Carlos López-Gil

A mouse PDX clinical trial reveals broad efficacy of niraparib and vc-seco-DUBA anti-HER2 ADC SYD985 in HER2/neu expressing endometrial cancer

Cristian P. Moiola, Carlos López-Gil, Marta Rebull, Ana M. Sotoca et autres

INTRODUCTION: Advanced and recurrent high-risk endometrial cancer (EC) frequently develops resistance to platinum-based chemotherapy, leaving patients with limited therapeutic options. Recent studies have shown that HER2 expression spans a broad spectrum of endometrial cancers, extending beyond HER2-amplified tumors, while functional homologous recombination …

es, nl, ps (code pays fourni par la source)

Aislamiento de un consorcio bacteriano con potencial de degradación de hidrocarburos

Tzu C. Fu-Chu, Carlos López-Gil, Andrés Tejeda-Rueda

El Proyecto de Aplicación Profesional (PAP) “Degradación de hidrocarburos e identificación de bio-enzimas”, desarrollado junto con la empresa MAQUISA, tuvo como objetivo estandarizar un método analítico para evaluar la degradación de diésel mediante técnicas espectrofotométricas. Aislar un consorcio bacteriano con potencial para …

Molecular classification improves preoperative risk assessment of endometrial cancer

Silvia Cabrera, Vicente Bebia, Carlos López-Gil, Ana Luzarraga-Aznar et autres

es, Tunisie (code pays fourni par la source)

Molecular profile in endometrial carcinoma: can we predict the lymph node status? A systematic review and meta-analysis

Ana Luzarraga Aznar, Vicente Bebia, Natalia R. Gómez-Hidalgo, Carlos López-Gil et autres

es (code pays fourni par la source)

547 Preclinical efficacy of the trastuzumab duocarmazine SYD985 as monotherapy or in combination with the PARP inhibitor niraparib in HER2-expressing endometrial cancer

Cristian P. Moiola, Carlos López-Gil, Marta Rebull, Melek Denizli et autres

es, nl (code pays fourni par la source)

219 Molecular profile is a strong predictor of the pattern of recurrence in patients with endometrial cancer

Ana Luzarraga-Aznar, Vicente Bebia, Carlos López-Gil, E. Chacón Vallés et autres

es (code pays fourni par la source)

1062 GynePDX: a new platform of preclinical models for endometrial and ovarian cancers

Beatriz Villafranca-Magdalena, Melek Denizli, Irene de la Calle, Marta Rebull et autres

es (code pays fourni par la source)

564 Molecular profile may preoperatively predict extrauterine spread in endometrial cancer patients: a retrospective analysis

Vicente Bebia, Carlos López-Gil, Ana Luzarraga-Aznar, Melek Denizli et autres

es (code pays fourni par la source)

Molecular profile is a strong predictor of the pattern of recurrence in patients with endometrial cancer

Ana Luzarraga Aznar, Vicente Bebia, Carlos López-Gil, Beatriz Villafranca-Magdalena et autres

es (code pays fourni par la source)

Endometrial adenocarcinoma recurring in the lung: impact of molecular profile and role of local therapies on prognosis

Ana Luzarraga Aznar, Vicente Bebia, Carlos López-Gil, Alexandra Giraldo et autres

es (code pays fourni par la source)

2022-RA-997-ESGO Lung recurrence of endometrial adenocarcinoma: impact of molecular profile and role of local therapies on prognosis

Ana Luzarraga, Vicente Bebia, Carlos López-Gil, María del Pilar Montoya et autres

es (code pays fourni par la source)

2022-RA-1475-ESGO Impact of molecular profiling on endometrial cancer staging: towards a personalized surgery

Sílvia Cabrera, Carlos López-Gil, Vicente Bebia, Anna Luzarraga et autres

Introduction/Background Molecular profiling in endometrial cancer(EC) is a consistent information that we may obtain from the pre-operative specimen. Nevertheless, its use for making surgical decisions has been barely explored. We aimed to analyze the impact of molecular profile in EC from a …

es (code pays fourni par la source)